Paradigm BioPharmaceuticals Ltd (PAR)

No endpoint from Phase2a Clinical Hay-fever Trial

Paradigm is an ASX listed biopharmaceutical company focused on repurposing the historic drug pentosan polysulphate sodium (PPS). PPS has non-steroidal anti-inflammatory properties and has potential for its novel use in the treatment of many inflammatory diseases such as Allergic Rhinitis (AR) (hay fever). PAR has announced that the Phase2a trial did not meet its primary endpoints, with the company speculating that the formulation of the drug needs optimising. This is an unexpected and disappointing result. However, the actual results of the trial have not yet been received and an independent expert will be brought in to assess the results and the likely next steps. We reduce our short-term price target to $0.35-$0.45, consistent with the price prior to the Phase 2a AR trial, but our risked valuation of $1.32 is currently maintained pending clarification of future progress in the AR trial. We place a Hold recommendation on PAR over the short term.

Key Points

  • PAR suggest a formulation issue or dose issue. PAR has announced that the muchanticipated Phase 2a allergic rhinitis (AR) clinical trial did not meet its endpoints via an intranasal delivery system - those being a total nasal symptom score and a peak nasal respiratory flow, using the current formulation. PAR suggest that the formulation used to deliver the drug PPS to the target tissues may need optimising. PAR also suggest that the dosage may require optimisation. This will inevitably delay the development of the AR program.
  • The inference is that it is not a drug efficacy or safety issue. The results of the trial are not yet known. We assume the timing on the release of the actual trial results remains within previous guidance, at around the end of June. PAR will engage an independent expert, as well as conduct its own analysis, to determine the next steps in the development of its allergic rhinitis program. Importantly, the company suggests that the safety of the potential drug is not in question and follows a successful, peer-reviewed pre-clinical study, demonstrating that PPS is a potent Th2 antagonist with a statistically significant outcome compared with the commercially available budesonide.
  • Other trials continue unaffected. PAR also announced that the results from the AR trial do not affect the other PPS-related programs proceeding as planned. PAR has received ethics approval for its Ross River Virus trial and is scheduled to enrol its first subjects during Q3 2017. Currently, PAR is recruiting subjects for its Phase 2a bone marrow lesion clinical study, which is scheduled for a read-out also in Q3. These trials will be utilising well established routes of administration, being subcutaneous or intra-muscular injection.
  • The next two trials already have human data. The two current programs, on bone marrow oedema and Ross River virus, already have human data signalling the efficacy of PPS for the next two trials. PAR believe these will provide significant value milestones for the company.
  • Recommendation and Valuation: The AR trial outcome is disappointing but it’s not yet over for PPS in the AR program. We reduce our short-term price target from $0.82 to between $0.35 and $0.45, being the price range prior to the start of the AR Phase 2 trial. We currently maintain our risked valuation at $1.32 pending clarification of the Phase 2 AR trial progress and change our Speculative Buy recommendation to Hold in the short-term.

Disclaimer

RCAN1411

This Research report, accurately expresses the personal view of the Author.

DJ Carmichael Pty Limited, members of the Research Team; including authors of this report, its directors and employees advise that they may hold securities, may have an interest in and/or earn brokerage and other benefits or advantages, either directly or indirectly from client transactions in stocks mentioned in this report. The analyst who wrote this report does hold securities in Paradigm BioPharmaceuticals Ltd. DJ Carmichael Pty Ltd provided corporate advice to Paradigm BioPharmaceuticals Ltd and was paid a fee for these services. DJ Carmichael Pty Ltd acted as Co-Lead Manager in a capital raising for Paradigm BioPharmaceuticals Ltd and was paid a fee for these services.

DJ Carmichael Pty Ltd is a wholly owned subsidiary of DJ Carmichael Group Pty Ltd ACN 114 921 247.

In accordance with Section 949A of the Corporations Act 2001 D J Carmichael Pty Limited advise that this email contains general financial advice only. In preparing this document D J Carmichael Pty Limited did not take into account the investment objectives, financial situation and particular needs (‘financial circumstances’) of any particular person. Accordingly, before acting on any advice contained in this document, you should assess whether the advice is appropriate in light of your own financial circumstances or contact your D J Carmichael Pty Limited adviser. D J Carmichael Pty Limited, its Directors employees and advisers may earn brokerage or commission from any transactions undertaken on your behalf as a result of acting upon this information. D J Carmichael Pty Limited, its directors and employees advise that they may hold securities, may have an interest in and/or earn brokerage and other benefits or advantages, either directly or indirectly, from client transactions. D J Carmichael Pty Limited believe that the advice herein is accurate however no warranty of accuracy or reliability is given in relation to any advice or information contained in this publication and no responsibility for any loss or damage whatsoever arising in any way for any representation, act or omission, whether express or implied (including responsibility to any persons by reason of negligence), is accepted by DJ Carmichael Pty Limited or any officer, agent or employee of D J Carmichael Pty Limited. This message is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended recipient or employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication and its attachments is strictly prohibited.

The Author of this report made contact with the Paradigm BioPharmaceuticals Ltd for assistance with verification of facts, admittance to business sites, access to industry/company information. No inducements have been offered or accepted by the company.

The recommendation made in this report is valid for four weeks from the stated date of issue. If in the event another report has been constructed and released on Paradigm BioPharmaceuticals Ltd, the new recommendation supersedes this and therefore the recommendation in this report will become null and void.

Recommendation Definitions

SPECULATIVE BUY – Potential 10% or more outperformance, high risk
BUY – Potential 10% or more outperformance
HOLD – Potential 10% underperformance to 10% over performance
SELL – Potential 10% or more underperformance
Period: During the forthcoming 12 months, at any time during that period and not necessarily just at the end of those 12 months. 

Stocks included in this report have their expected performance measured relative to the ASX All Ordinaries index. DJ Carmichael Pty Limited’s recommendation is made on the basis of absolute performance. Recommendations are adjusted accordingly as and when the index changes.

To elect not to receive any further direct marketing communications from us, please reply to this email and type 'opt out ' in the subject line. Please allow two weeks for request to be processed.

© 2017 No part of this report may be reproduced or distributed in any manner without permission of DJ Carmichael Pty Limited.

Paul Adams

Head of Research

Paul joined DJ Carmichael in 2006 as a Resource Analyst. Paul has an honours degree in Geology, is a member of the Australian Institute of Mining and Metallurgy and has 16 years experience in the mining industry in exploration, open pit, underground and operational roles, both in Australia and overseas. Before joining the company, he was Chief Geologist and Evaluations Manager at Placer Dome's Granny Smith mine. Paul has a Graduate Diploma in Applied Finance and Investment, fromthe Financial Services Institute of Australasia.